Physician profile
Christopher V Johnson
NPI 1205975448
$2,772.11
in general payments reported to CMS, 2019-2025
16 companies · $714 in 2025
The $714 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $203 · 2021: $333 · 2022: $247 · 2023: $308 · 2024: $341 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $554.15 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $547.28 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $431.65 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $346.98 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $246.16 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $143.68 | 2019-2025 | Fanapt |
| Abbvie INC. | $82.83 | 2021-2025 | |
| Axsome Therapeutics, INC. | $75.92 | 2024-2025 | Auvelity |
| Allergan, INC. | $70.92 | 2019 | |
| Almatica Pharma LLC | $51.61 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $45.49 | 2023-2024 | Rexulti |
| Tris Pharma INC | $43.75 | 2022-2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $42.99 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $36.20 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.43 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.